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CHAPTER ONE
Introduction
1.1 Neurotransmission
The brain is the most complex organ in the human and animal
body. The human brain is comprised of 100 billion neurons with trillions
of synapses.2 Neurons consist of a cell body, which contains the nucleus
and cytoplasmic organelles, surrounded by small dendritic branches and
an axon through which an action potential is propagated to the axon
terminals. A neuron’s function is specialized for different tasks based on
the neurotransmitter(s) it expresses and the brain regions it innervates.
Since

neurons

are

not

directly

interconnected,

adjoining

neurons

communicate chemically through junctions called synapses (Figure 1-1).
This chemical communication is accomplished using neurotransmitters,
which are biogenic chemicals released from neurons into the synapse.1
There are many classes of neurotransmitters, such as amino acids,
peptides, and monoamines.1
Neurotransmitters are synthesized in the cytoplasm of the neuron
and are stored in vesicles, found near the plasma membrane of the nerve
terminal. Upon propagation of a signal, the membrane is depolarized via
the influx of positive ions into the cell through membrane-bound ion
channels, which causes the inside of the membrane to be more positive.
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When the depolarization is sufficient to create an action potential, an
influx of Ca2+ will be triggered at the nerve terminal, promoting fusion of
vesicles

to

the

pre-synaptic

plasma

membrane

and

release

of

neurotransmitters into the synapse. This process is called exocytosis.
Released neurotransmitters can diffuse across the synaptic cleft and bind
to specific receptors on the postsynaptic neuron, which leads to an
electrical

or

biochemical

alteration

in

the

postsynaptic

cell.

Neurotransmitters are cleared from the synaptic cleft, which terminates
the action of the neurotransmitter, by plasma membrane transporters on
pre- or post-synaptic terminals. Following transporter-mediated uptake,
the neurotransmitter can be recycled and be repackaged into vesicles.
Additionally, neurotransmitters in the synaptic cleft can be enzymatically
degradated or transported to neighboring glial cells.1
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Figure 1-1. An illustration of a synapse
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1.2 Amino Acid Neurotransmitters
The amino acid family of neurotransmitters can be divided into two
sub-groups: excitatory and inhibitory amino acid transmitters.2 Excitatory
amino acids, including glutamate, aspartate, cysteate and homocysteate,
stimulate neurotransmission by permitting an excess of positive charge
inside the neuron resulting in depolarization of the neuron. On the other
hand, inhibitory amino acids, including gamma amino butyric acid
(GABA),

glycine,

and

taurine,

produce

synaptic

inhibition

(i.e.

hyperpolarization) by permitting a net positive charge to flow out of the
cell or by making the cell membrane negatively charged.1, 2 In the central
nervous system (CNS), the most abundant inhibitory and excitatory amino
acid neurotransmitters are GABA (Figure 1-2A) and glutamate (Figure 12B), respectively.2 In comparison, the concentration of GABA and
glutamate in the brain is in the range of µmoles/gm, where as the
concentration of monoamines are in the range of nmoles/gm.2
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A

B

Figure 1-2. Representative amino acid chemical structures. (A) Chemical
structure of the excitatory amino acid glutamate. (B) Chemical structure
of the inhibitory amino acid gamma aminobutyric acid (GABA).
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Gamma-aminobutyric acid
GABA is a non-protein amino acid that is heterogeneously
distributed throughout the brain, with the highest concentrations in the
substantia nigra, hippocampus, hypothalamus, and the basal ganglia.2,

3

GABA signaling regulates many neurological processes and 30-40% of all
synaptic terminals contain GABA.3
GABA

is

synthesized

from

alpha-ketoglutarate,

which

is

an

intermediate of the citric acid cycle. During the synthesis, alphaketoglutarate is converted into glutamate by the action of GABA
transaminase (GABA-T), which is then catalyzed by glutamate acid
decarboxylase

(GAD)

to

produce

GABA1

(Figure

1-3).

Like

other

neurotransmitters, GABA is packaged into vesicles in the presynaptic
terminal and is released into the synaptic cleft following depolarization of
the neuron. In the synaptic cleft, the released GABA is available to couple
with membrane associated receptors found pre- and post-synaptically.1
There are two major types of GABA receptors: GABAA, which is an
ionotropic receptor where the GABA binding site is incorporated with a
chloride ion channel and GABAB, which is a metabotrophic, G-protein
coupled receptor consisting of seven transmembrane domains.3
GABAA receptors are predominantly found post-synaptically. Upon
activation, GABAA receptors increase membrane permeability to chloride
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ions, leading to hyperpolarization of the neuron and inhibition of action
potential propagation through the post-synaptic neuron. The inhibition of
neuronal signaling mediated by GABAA receptors is rapid, occurring in 1
to 10 ms, and sensitive to low concentration of GABA.1 The action of
GABAA

receptors

can

be

selectively

inhibited

by

the

competitive

antagonist, bicuculline.1,2
GABAB

receptors

are

mostly

presynaptic

and,

like

other

metabotrophic receptors, they regulate cellular metabolic processes
through phosphorylation of protein kinases and activation of second
messengers.1 Since GABAB receptors are extrasynaptic (outside the
synapse), they require higher concentrations of GABA to diffuse away from
the synaptic cleft to bind and activate them. When located on pre-synaptic
GABAergic terminals, extrasynaptic GABAB receptors act as autoreceptors,
whose activation inhibits further synaptic release of GABA. GABAB
receptors can also be located on glutamatergic nerve terminals, where
they act as heteroreceptors, which inhibit the release of glutamate upon
GABA activation. For example, baclofen is a competitive agonist which
interacts with the GABA binding site of GABAB receptors to activate
receptor function. Alternatively, GABAB function can be inhibited by the
competitive antagonist, phaclofen.
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Extraneuronal GABA is removed from the synaptic cleft by plasma
membrane GABA transporters and repackaged into vesicles in GABAergic
nerve terminals.4 GABA uptake can also be mediated by glial cells. Similar
to neurons, GABA taken up in glial cells is converted into succinic acid
semialdehyde by the action of GABA transaminase. Removal of the amino
group of GABA is accepted by α-ketoglutarate to generate glutamic acid
and thereby conserve the available supply of GABA. However, glutamic
acid formed in glial cells cannot be converted to GABA since glial cells lack
GAD. Rather, it is transported into the neuron, which regenerates GABA
by the action of GAD to be packaged into vesicles for future release.
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Figure 1-3. The metabolic pathway of GABA synthesis and degradation
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Glutamate
Glutamate is the major stimulatory neurotransmitter, as it is found
in over half of the synapses in CNS.3 As such, glutamate has important
physiological roles in regulating synaptic plasticity, cognitive processes,
learning and memory.1,

2

Neuronal glutamate is mainly synthesized from

glucose through the Krebs cycle and transamination of α-keto-glutarate,
since glutamate is unable to cross the blood-brain barrier.3 In the
cytoplasm, glutamate is synthesized from glutamine by the action of
glutaminase (Figure 1-4).
Like other neurotransmitters, glutamate is stored in vesicles,
released in a Ca2+-dependent manner following stimulation by a nerve
impulse, and binds to specific receptors on the neuronal membrane.2
There are two types of glutamate receptors: the ionotropic receptors have a
glutamate binding site and an ion channel incorporated into the same
complex and the metabotropic receptors are coupled to heterotrimeric Gproteins.1, 2
The three glutamate ionotropic receptors; N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoazole propionic acid (AMPA),
and kainite receptors; are named based on the ability of these drugs to act
as selective agonists.2 When glutamate binds to these receptors, it causes
the Na+ ion channel coupled to the receptor to open. By increasing the
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membrane permeability to Na+ ions, glutamate promotes depolarization of
the neuronal membrane and excitation of neurons. 2 Like GABA ionotropic
receptors, glutamate ionotropic receptors also mediate fast transmission.
Like

other

metabotropic

receptors,

glutamate

metabotropic

receptors (mGluRs) regulate intracellular protein kinase cascades, which
affect cellular metabolic processes. There are eight different types of
glutamate metabotropic receptors, named mGluR1 through mGluR8,
depending on their amino acid sequence. mGluRs are located on the postsynaptic membrane, where they regulate various ligand- and voltage-gated
ion channels to promote neuronal depolarization. However, since mGluRs
are not directly coupled to ion channels, neuronal excitation occurs on a
much slower timescale following glutamate activation compared to
ionotropic receptors.
The concentration of glutamate in the extracellular environment is
primarily regulated through uptake via glutamate transporters on
adjoining glial cells. In glial cells, glutamate is converted into glutamine by
glutamine synthetase before being transported out of the cell. This
glutamine is taken up by glutamatergic neurons and subsequently
reconverted into glutamate by glutaminase.1
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Figure 1-4. Neuronal synthesis and degradation of glutamate. Cytosolic
glutamate (glu) is synthesized from glutamine (gln) by the enzyme
glutaminase, where cytosolic glu is stored in synaptic vesicles. After an
action potential, the synaptic vesicles fuse with the presynaptic membrane
and release glu into the synapse.
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1.3 Neurochemical measurements and analytical challenges with
GABA and glutamate
The measurement of amino acid neurotransmitter levels in different
brain regions is crucial to investigate the underlying mechanism and
design

effective

therapies

for

associated

neurological

diseases.

Microdialysis is one method used to measure neurotransmitter levels. This
technique is useful for in vivo monitoring of extracellular levels of
neurotransmitters present in the brain. Alternately, neurotransmitters can
be measured in vitro using brain slices or punches which predominantly
give the intracellular levels of neurotransmitters.
Analytical challenges with GABA and glutamate
Since the neurotransmitter levels in the extracellular space
fluctuate rapidly, a method with improved temporal resolution is required
for accurate measurement of extrasynaptic neurotransmitter levels.
Although some researchers have obtained fast temporal resolution using
capillary

electrophoresis

(CE)

and

microfluidics,

still

in

most

neurochemical laboratories HPLC is the most popular instrument to
analyze microdialysis samples due to commercially availability and easy
instrumental setup. However, it is very challenging to improve the
temporal resolution with HPLC due to slower separation compare to CE
and microfluidics. Thus, the coupling of this sampling method to HPLC
with shorter run time is desired.
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Detection of amino acid neurotransmitters poses an analytical
challenge, as they are not naturally electroactive and most amino acids do
not possess fluorescent or strong UV absorbance characteristics. To
circumvent this problem, pre-column derivatization is used to make them
electroactive or fluorescence.
Most pre-column derivatization for glutamate and GABA detection
uses ortho-phthaladehyde (OPA)/ β-mercaptoethanol (βME) (Figure 15A.)5,6 However, several studies have shown that the GABA OPA/βME
derivative is relatively instable.7,8,9,10 An excess of underivatized OPA can
electrophilically attack the isoindole ring system and enhance the
autoxidation of the product9. Alternatively, 3-mercaptopropionic acid,
tertiary butylthiol, and sodium sulphite have been used instead of βME to
make the OPA derivative more stable since they have less oxidizing power
than

βME.11,12

As

an

alternative

reagent

to

OPA,

naphthalene

decarboxylaldehyde (NDA)/cyanide ion (CN-) has been developed because
of its increased stability and higher yield of fluorescent intensity (Figure 15B).7
Previous studies have shown that simultaneous determination of
both glutamate and GABA required run times up to 60 min, to separate
GABA

from

other

co-eluent

peaks.

However,

significant

research

advancements with the conventional C18 pack column have been made,
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and run time has been improved from 20 to 30 min to about 10 min.7,8, 13,6
One approach that has been used recently to decrease run time is to use a
monolithic column for glutamate and GABA separation.14 A monolithic
column maintains a lower backpressure even when system conditions are
operated at high flow (typically > 1 mL/min) rates due to the higher
porosity of these columns, which is about 80% greater than a
conventional C18 packed column. Additionally, the higher porosity of silica
monolithic columns provides a greater surface area, leading to better
separation of small molecules, such as amino acids. Since monolithic
columns can be operated at higher flow rates without loosing separation
efficiency compared to packed columns, higher sample throughput, one of
the demand in the amino acid assay in microdialysis samples can be
achieved.14
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(B)
CN

CHO
+

R NH 2
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Naphthalene-2.3dicarboxaldehyde
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Amino Acid

Isoindol

Figure 1-5. General reaction scheme for the formation of fluorescence
active isoindolic products from amino acids with OPA and NDA. (A) The
reaction of OPA with a primary amino acid in the presence of βME. (B) The
reaction of NDA in the presence of cyanide.
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Microdialysis
Microdialysis is a perfusion-based sampling method that permits
small biochemicals to pass through a semi-permeable dialysis membrane
down their concentration gradient (Figure 1-6). In the brain, microdialysis
is used to measure changes in neurotransmitter levels in the extracellular
space of intact, living tissue. An effective in vivo sampling method to
monitor

neurotransmitters

in

the

brain

should

provide

chemical

versatility, adequate spatial resolution to permit detection in small,
distinct brain regions, and fast temporal resolution to detect rapid
changes in extraneuronal neurotransmitter levels. A main advantage of
microdialysis over other techniques to measure neurotransmitters in vivo,
such as positron emission tomography (PET), are that this technique has
multi-analyte capability, conferred by its ability to be coupled to high
performance liquid chromatography (HPLC) or capillary electrophoresis
(CE).15 An additional advantage of microdialysis over other in vivo
analytical techniques is that it can be used to estimate extracellular basal
levels

of

neurotransmitters.

However,

since

the

extraneuronal

concentrations of most neurotransmitters are extremely low in the brain,
it is critical to couple microdialysis with highly sensitive analytical
techniques.
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Figure 1-6. Schematic of a microdialysis probe
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Microdialysis was developed in 1974 by Ungerstedt and Pycock, who
introduced a perfusion device, called a dialytrode, which consisted of two
tubes connected to a dialysis membrane.16 Since then, this technique has
been refined and widely used in brain research to measure the dynamic
changes of neurotransmitters. The microdialysis sampling technique relies
on a small probe inserted into tissue to sample small solutes.17 A
microdialysis probe consists of a cylindrical semi-permeable membrane,
typically made from cuprophan, which is connected to an inlet and outlet
tubing.17 For example, the molecular weight cut-off of the dialysis
membrane that we use is 6 kDa. Since the dialysis membrane is
hydrophilic and porous, diffusion occurs through the water space in the
membrane, greatly increasing the mass transport of the analyte across the
membrane.17
Once a probe is introduced to a biological matrix, it is constantly
being perfused with artificial cerebrospinal fluid (aCSF). ACSF is isoosmotic to the extracellular fluid of the tissues being sampled. The
perfusion medium is delivered at a constant flow rate using syringe pumps
(Figure 1-7). When sampling from a freely-moving animal in vivo, the
animal is housed in an open container and the probe is connected to a
liquid swivel, which allows for free movement of the animal.
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Microdialysis sampling relies on the principles of diffusion and size
exclusion. Thus, the ionic strength and composition of the perfusion
medium should closely resemble the extracellular fluid, to prevent the loss
of fluid from either the perfusion medium or the extracellular fluid.39
Small molecules, with a molecular weight below the membrane cut-off,
diffuse down their concentration gradient through the membrane into the
perfusion medium. The resulting dialysate is either collected for later
analysis or transported directly to an on-line analytical system. Since the
microdialysis probe diameter is much larger (size of our probe is ~ 240
µm) than the synaptic cleft, it can not directly monitor changes in
neurotransmitters at the synaptic level. Rather, it can be used to detect
changes in neurotransmitters from the vicinity of the synaptic cleft,
referred to as the extrasynaptic space. As a result, dialysis levels of a
neurotransmitter represent the average concentration of the target
neurotransmitter in that brain area.
One of the critical factors that can impact the effectiveness of
microdialysis sampling is analyte recovery. Recovery can be represented in
terms of absolute recovery, which is the mass of analyte collected over a
certain time period, or relative recovery, which is the concentration of
analyte in the dialysate divided by the concentration in the sample
media.29 Numerous factors can affect the recovery of analytes through the
microdialysis probe such as molecular weight cutoff of the dialysis
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membrane, temperature of the tissue, and membrane materials. However,
the focus here will be on flow rate, which the experimenter can directly
control. Recovery rate is impacted by perfusion flow rate, such that a
higher flow rate will lead to higher absolute recovery and lower relative
recovery. This is due to the fact that a higher flow rate will shorten the
time an analyte has to reach equilibrium at the probe surface. As a result,
a flow rate which gives adequate relative recovery and absolute recovery to
meet the instrument concentration detection limit and mass detection
limit should be selected. Although the smaller diameter probes minimize
tissue damage and improve spatial resolution, this modification negatively
impacts the recovery of an analyte by reducing the surface area of the
membrane.17
Microdialysis samples can be analyzed either on-line or off-line. An
on-line method requires a rapid and analytical method, since dialysate
samples are continuously being collected for a given period of time and
then automatically injected on to the analytical system. In comparison,
samples are collected in a separate step in off-line assays and stored for
later analysis. Although on-line analysis of samples allows for detecting
the analytes during the experiment with minimal sample handling, off-line
analysis is useful for assays that are slow due to long derivatization time
or require greater amount of time to separate the analytes. While smaller
fractions can be collected to increase the temporal resolution of offline

22

assays, the mass detection limit of the analysis instrument is critical as
the amount of analyte per sample is decreased.15 Thus, increased
temporal resolution requires the coupling of microdialysis with analytical
instrumentation that has a high sensitivity and is capable of high
throughput. In an effort to improve temporal resolution of microdialysis
sampling, researchers have coupled microdialysis with capillary liquid
chromatography, capillary electrophoresis, and microfluidics.18,12,19
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Figure 1-7. Schematic of the basic components to a microdialysis
experimental setup.
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Tissue Content
Although

microdialysis

is

useful

for

in

vivo

monitoring

of

extraneuronal neurotransmitter concentrations, it is also important to
quantitate the intracellular levels of neurotransmitters using dissected
brain regions of interest. It has been showed that between 70 and 80% of
total tissue level GABA serve neurotransmitter function.7 Total tissue level
neurotransmitter levels predominantly are reflective of intraneuronal
stores, which comprises of the amino acids levels within vesicles or glial
cells. Unlike in vivo microdialysis, tissue content is an ex vivo technique.
The animal is sacrificed and the brain is rapidly harvested. The brain is
then dissected into discrete brain regions of interest. Tissue content
provides a global perspective of intracellular neurotransmitter stores
within discrete brain regions.
1.4 Research objectives
The analytical objective of the research described in this thesis is to
develop and optimize a fast method using HPLC to rapidly measure the
concentrations of GABA and glutamate in microdialysis samples. The first
neurochemical objective is to determine the effect of several endogenous
and exogenous factors, such as brain-derived neurotrophic factor (BDNF),
alcohol, and age, on the neuronal levels of striatal GABA and glutamate.
The second neurochemical goal is to determine if excess exposure to
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manganese influenced striatal GABA and glutamate levels compared to
saline-treated mice. Finally, analysis of GABA and glutamate in brain
tissues of selected brain regions by HPLC also were done to compare the
concentration of GABA and glutamate with the previously reported values
obtained by magnetic resonance spectroscopy (MRS) with the purpose of
validating MRS as an analytical method to measure amino acid
neurotransmitters.
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CHAPTER TWO
Materials and Methods
2.1 Introduction
The focus of this chapter is to illustrate the methods used to
conduct the research described in this thesis. The separate sections will
describe and explain the techniques for animal surgery, microdialysis
sampling, and optimization of analyte detection with high performance
liquid

chromatography

(HPLC).

Additionally,

intracellular

levels

of

glutamate and GABA will be analyzed from mouse brain tissue extracts by
HPLC and these tissue concentrations will be compared to those
previously obtained in the laboratory of Dr. Galloway (Department of
Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne
State University) using proton magnetic resonance spectroscopy (1H-MRS).
2.2 Reagents
Napthalene-2,3-dicarboxyaldehyde

(NDA),

di-sodium

hydrogen

orthophosphate (Na2HPO4), and ethylenediaminetetraacetic acid (EDTA)
were purchased from Fluka (Switzerland). Glutamate (Glu), and GABA
were obtained from Sigma-Aldrich (St Louis, MO). O-Phthaldialdehyde
(OPA) was obtained from Alfa Aesar (Germany). Sodium chloride (NaCl),
sodium phosphate monobasic (NaH2PO4), sodium bicarbonate (NaHCO3),
calcium chloride (CaCl2), and boric acid from EMD chemicals (Japan).
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Potassium chloride (KCl), magnesium chloride (MgCl2), HPLC-grade
methanol and ultrafiltered water from Fisher scientific (Fair Lawn, NJ). All
aqueous solutions were filtered through Millipore 0.22 µm membrane
filters.
2.3 Animals
Wildtype (BDNF WT) mice, BDNF+/- (heterozygote) mice, and male
C57Bl/6J mice were purchased from Jackson Laboratories (Bar Harbor,
ME). A colony of BDNF WT and BDNF+/- mice was maintained in-house at
Wayne State animal care facilities. To verify the presence of the transgene,
genotype identification by polymerase chain reaction (PCR) from their tail
tissues were done. Approximate age of mice used in these experiments
was 8-16 weeks old. Mice were housed in groups of 5 to 10 animals per
cage with food and water ad libtum on a 12-hr light-dark cycle.
Experimental protocols adhered to the National Institutes of Health
Animal Care Guidelines and were approved by the Wayne State University
Institutional Animal Care and Use Committee.
2.4 Stereotaxic Surgery
Adult male mice were anaesthetized with 2,2,2-tribromo-ethanol/2methyl-2-butanol (Avertin) administered in a volume 23 mL/kg by
intraperitoneal (i.p.) route.20 The eyes were protected with sterile
ophthalmic ointment during surgery. The skin over the skull was shaved,
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sterilized with Betadine and alcohol, and incised. The exposed skull was
cleaned and dehydrated with 10% hydrogen peroxide (H2O2). Mice were
placed on a stereotaxic frame equipped with a palate adapter and two burr
holes were drilled. One hole was used to insert the guide cannula
(CMA/Microdialysis AB, Chlemsford, MA) and the second was used for to
insert a bone screw (BASi, West Lafayette, IN) for anchoring. In all these
experiments, the guide cannula was targeted to the dorsal striatum
(caudate-putamen; CPu) using coordinates (anterior + 0.8, lateral +1.3,
ventral -2.5 from Bregma) determined from the mouse brain atlas and
further refined by empirical determination.21 The guide cannula was
secured to the skull with dental cement (CO-ORAL-LTE DENTAL Mfg. Co.,
Diamond springs, CA). At the end of the experiment, animals were
sacrificed and the brain was rapidly removed and sectioned using a
Vibratome (Vibratome, St. Louis, MO) to identify probe location. The
location of the dialysis probe was visually inspected from the coronal
slices (300 µm) to confirm the placement of the probe was indeed in the
dorsal CPu (Figure 2-1).

29

Figure 2-1. A cartoon of a mouse coronal brain slice illustrating proper
placement of the microdialysis probe in the dorsal striatum (CPu).22
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2.5 In vivo microdialysis
Four microdialysis experiments were conducted to evaluate the
effect of 1) BDNF, 2) acute consumption of ethanol, 3) exposure to
manganese, and 4) age on extracellular levels of GABA and glutamate. In
all the following experiments, a microdialysis probe (2 mm length x 240
µm diameter cuprophan, 6000 Da MW cutoff) was inserted into the guide
cannula in the CPu following surgical recovery (~ 6 hrs). The probe was
perfused overnight with artificial cerebrospinal fluid (aCSF; 147 mM NaCl,
3.5 mM KCl, 1.0 mM CaCl2, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 2.5 mM
NaHCO3, pH ~ 7.4) at a flow rate of 0.7 µl/min. After a 14-h equilibration
period, microdialysis samples were collected. The dialysate samples
collected off-line were stored at -80°C until they were derivatized for
analysis by HPLC.
Experiment 1: To evaluate the effects of high K+ on the release of glutamate
GABA in BDNF WT and BDNF+/- mice.
Six baseline samples were collected from either BDNF WT or
BDNF+/- mice at 10-min intervals followed by a 20-min perfusion of highpotassium (120 mM) aCSF (30.5 mM NaCl, 120 mM KCl, 1.0 mM
NaH2PO4, 1.2 mM MgCl2.H2O, 1.0 mM CaCl2, pH ~ 7.4).23 After the
perfusion of high-potassium aCSF, samples were collected with normal
aCSF every 10 minutes for 2-h.
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Experiment 2: To evaluate the effects of ethanol on striatal extracellular
concentrations of GABA and glutamate in BDNF WT and BDNF+/- mice.
Three baseline samples were collected from either BDNF WT or
BDNF+/- mice at 10-min intervals. The mice were then administered saline
(0.9% NaCl, i.p.) and samples were collected every 10 min for the next 40
min. After collection of the fourth saline sample, mice were administered
ethanol (2 g/kg, i.p.) and 10-min samples were collected for the next two
hours.
Experiment 3: To evaluate the effect of manganese exposure on the
extracellular concentration of GABA in the CPu.
Prior to dialysis surgery, mice were injected subcutaneously with
either 0.1 mL of manganese (II) chloride tetrahydrate (MnCl2.4H2O; 50
mg/kg) or 0.9 % NaCl. Mn treatment was repeated every third day for a
week (days 1, 4, and 7). Surgery for guide cannula implantation in the
CPu was performed on either day 8, 14, or 28, which was 1, 7 or 21 days
following the last Mn treatment. Following probe insertion and a 10 h
equilibration period, five baseline samples were collected every 10 min.
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Experiment 4: To evaluate the effect of age on the extracellular
concentrations of glutamate and GABA in the CPu in mice deficient with
BDNF.
Stereotaxic surgery for guide cannula implantation was performed
on BDNF WT and BDNF+/- mice at 18 months of age. Basal and
potassium-stimulated levels of glutamate and GABA in the CPu were
monitored following probe insertion as outlined in experiment 1.
Derivatization procedure of dialysis samples
Stock standards of NDA (6 mM) in 50:50 acetonitrile (CH3CN) and
borate buffer (0.1 M, pH 9.5), KCN (10 mM) in borate buffer, and amino
acid standards (10 mM) in aCSF were prepared weekly and stored at 4ºC.
The amino acids were derivatized by adding: 20 µl of borate buffer (0.1 M),
5 µl of KCN (10 mM), and 5 µl of NDA (6mM) to 7 µl of standard solution
or dialysate sample. The resulting mixture was vortexed and allowed to
proceed at room temperature in the absence of light for approximately 1015 min, and immediately afterward 20 µl of the derivatization product was
injected onto the HPLC.
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2.6 Mouse brain tissue levels of GABA and glutamate
Tissue collection
Unanesthetized male mice (8 to 16 weeks old) were sacrificed by
cervical dislocation. The brain was immediately removed, placed on an icecold matrix, and sectioned into 2 mm thick slices. Several tissue punches
(2.1-mm diameter, approx. wet weight of 4 mg) were microdissected from
each slice to isolate various brain regions, including the cerebellum (CB),
nucleus accumbens (NAc), striatum, and hippocampus (Figure 2-2). The
punches were immediately frozen on dry ice, placed in 1.5 mL
microcentrifuge tube, and stored at -80ºC for later analysis with HPLC.
Sample preparation procedure
Tissues were removed from the freezer, weighed, and then
homogenized with 80 µl of 50 µM EDTA in 400 mM HClO4 solution. The
homogenized tissue samples were neutralized with 0.1 M borate buffer
(1:10) and centrifuged (14,000 rpm, 30 min, 4 ºC). The supernatant (100
µl)

was

removed

derivatization.

and

placed

in

a

microcentrifuge

tube

for

the
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Figure 2.2. Representative coronal dissection slices with 2 mm thickness.
Circles on brain slices indicate where tissue punches for discrete brain
regions are approximately taken. Key for brain regions of interest: AST,
anterior striatum; NAc, nucleus accumbens; HC, hippocampus; CB,
cerebellum. Photo courtesy of Dr. Matthew Galloway, Wayne State
University School of Medicine.
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Derivatization procedure
The derivatization procedure was based on a protocol previously
described by Clarke et al. (2007).13 Briefly, 100 µl of either standard or
sample supernatant was added to a solution containing 0.1 M borate
buffer (900 µl, pH 9.5), 10 mM potassium cyanide (200 µl) and 6 mM NDA
(200 µl). The samples were then vortexed and the reaction proceed for 15
at ambient temperature in the absence of light. The derivatization product
(20 µl) was injected onto the HPLC system.
2.7. Detection of amino acid neurotransmitters in dialysis samples
Spectrofluorophotometer experiment
Fluorescence intensity comparison of o-phthalaldehyde (OPA) and
naphthalene-2,3-dicarboxaldehyde

(NDA)

were

performed

using

a

Shimadzu RF-5301PC spectrofluorophotometer (Shimadzu, Columbia,
MD). Excitation wavelengths of OPA and NDA derivatives were set at 337
and 420 nm, respectively. Emission intensity of NDA and OPA derivatives
were measured at the range of between 400 – 600 nm and 300 – 600 nm,
respectively.11,13
Fluorescence experiments were performed using a quartz cell. The
amino acids, GABA and glutamate, were derivatized with either NDA or
OPA and the duration and intensity of the fluorescent signal was
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monitored. To derivatize the amino acids with NDA, 0.7 mL of the amino
acid standard (< 1 µM) was added to working solution containing 0.1 M
borate buffer (pH 9.5), 10 mM KCN, and 5 mM NDA.24 The OPA
derivatization protocol was based on a method described by Rowley et al.55
Briefly, 0.08 M OPA was prepared by dissolving OPA (22 mg) in 0.5 mL of
absolute ethanol and 0.9 mL of sodium tetraborate buffer (0.1 M, pH
10.4). This solution was prepared daily and immediately reacted with a 1
mL of a GABA or glutamate standard in a quartz cell.
HPLC equipment and conditions
The binary gradient HPLC system was constructed using two
Shimadzu LC-20AD HPLC pumps (Shimadzu, Colombia, MD) connected
with a mixer, on-line degasser, and high pressure flow channel selection
valve. Mobile phase A consisted of 0.1 M Na2HPO4 in 50 µM of EDTA (pH
5.7; adjusted with 6 M HCl), and mobile phase B consisted of 100%
methanol. The gradient elution was performed at room temperature using
the following conditions: 0 min 40% B (flow rate of pump B: 0.8 mL/min),
2.00 min 50% B (flow rate of B: 1 mL/min) for a total flow rate of 2
mL/min. Dialysate samples (10 µL) were injected onto a Chromolith
column (RP-18e, 100 x 4.6 mm, EM Science, Germany) for separation of
GABA and glutamate. Fluorescence intensity of the effluents was
measured by Jasco FP 2020 fluorescence detector (Jasco, Tokyo, Japan).
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The excitation and emission wavelengths for NDA-derivatized amino acids
were set to 420 and 480 nm, respectively. Known standards were used to
identify and quantify the GABA and glutamate peaks in the HPLC
chromatogram. Characteristic retention times for GABA and glutamate
were 4.5 and 1.8 min, respectively. The peak areas of GABA and
glutamate were integrated with the calibration curve of known standards.
Concentrations were expressed in nM ± standard error of the mean (SEM).
2.8 Data analysis
All data were analyzed using GraphPad Prism 5 software. The
average concentration of baseline samples were set at 100% and all the
other value are expressed as percentage of the average of baseline
samples. To determine if extracellular glutamate and GABA levels are
significantly different between BDNF WT and BDNF+/- mice a Student’s ttest was performed. The t-test probability “P” value determines whether
the compared two means are “different” from each other and the level of
significance was set at P < 0.05. All values present as means ± standard
error of the mean (S.E.M). When comparing means of all the mice, the
data were analyzed by a one-way analysis of variance (AVOVA) followed by
a Tukey post-hoc test using GraphPad Prism software. Linear regression
analysis was done to determine the linearity of calibration curves.
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CHAPTER THREE
METHOD OPTIMIZATION
While a number of studies have demonstrated the stability and
fluorescence

properties

of

isoindole

products

obtained

from

NDA

dervitization, the spectrofluoromety studies described in this chapter will
compare the stability, fluorescence intensity, and the kinetic properties of
OPA and NDA derivatives of GABA and glutamate. These optimized
parameters will be applied to determine the concentrations of GABA and
glutamate in dialysis samples obtained from all microdialysis experiments
conducted in the CPu of mice.
3.1 Comparison of glutamate and GABA detection with NDA and OPA
Fluorescence intensity comparison of OPA and NDA were performed
as described in section 2.3. The excitation and emission wavelengths for
OPA derivatives were 337 and 454 nm and NDA derivatives were 420 and
480 nm, respectively. The fluorescence intensities of OPA and NDA
derivatives are shown for identical concentrations (1 µM) of GABA (Figure
3-1A) and glutamate (Figure 3-1B) as a function of time. These profiles
show a rapid increase in fluorescence intensity for both OPA and NDA
derivatives due to the rate of formation of isoindolic products. However,
the plateaus for GABA and glutamate fluorescence emission with NDA and
OPA were considerably different. Fluorescence intensity of NDA derivatives
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of GABA and glutamate are about 2.5 and 2 fold higher than that of OPA
derivatives, respectively.
The kinetics of GABA and glutamate labeling by NDA was similar,
and in both cases, the reaction was completed in approximately 20 min.
After reaching a maximum, the fluorescence intensity of NDA derivatives
remained stable for about one hour at room temperature. Although the
fluorescence

intensity

of

OPA

derivatives

were

considerably

lower

compared to NDA derivatives, the OPA derivatization reaction was
completed in less than 5 min. The life-time of the fluorescence for OPA
products was also short-lived and started to decrease 25 min after
reaching the maximum. Together, these data demonstrate NDA derivatives
of both GABA and glutamate have a higher fluorescence intensity and
stability compared to OPA derivatives, thus confirming the higher
sensitivity of NDA derivatization to detect amino acids.
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Figure 3-1. Fluorescence intensities of isoindole derivatives of (A) GABA
and (B) glutamate formed by OPA (open symbols) or NDA (closed symbols)
derivitization. Fluorescence intensity is define as arbitrary units (a.u).
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Method Validation
The linearity was determined for glutamate (Figure 3-2A) and GABA
(Figure 3-2B) standard calibration curves in the range of 5 to 200 nM. The
correlation coefficient yielded by linear regression analysis was 0.9995
and 0.9980 for GABA and glutamate, respectively. The limit of detection
(LOD) which is three times signal to noise ratio for GABA and glutamate
(20 µl injection volume) was 6 nM and 10 nM, respectively. The
repeatability of the optimized method was determined by injecting 50 nM
and 100 nM GABA and glutamate standards repeatedly five times. The
repeatability was 2.4% (R.S.D) for GABA and 3.5% (R.S.D) for glutamate.
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Figure 3-2. Linear relationship between detector response and the
amount of glutamate and GABA injected. (A) Calibration curve of
concentration of glutamate (nM) versus area of corresponding peaks. (B)
Calibration curve of concentration of GABA (nM) versus area of
corresponding peaks.
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3.2 Separation and
microdialysis samples

detection

of

GABA

and

glutamate

from

A binary gradient was used to separate glutamate and GABA for
simultaneous HPLC detection. The mobile phase composition was based
on a study by Clark et al. (2007) with modifications.13 GABA and
glutamate peak separation was optimized by altering the percentage of
methanol in the gradient profile; pH of the sodium dihydrogen phosphate
buffer (buffer A); and the flow rate. The retention of glutamate, but not
GABA, was sensitive to pH changes in buffer A. Increasing the pH of buffer
A at 0.1 intervals from 5.3 to 5.9 enhanced the separation of glutamate,
with optimal separation of glutamate at pH 5.7. The detection of GABA
from striatal microdialysis samples was challenging, since GABA is in low
concentration in the dorsal striatum (CPu) and often co-elutes with nonspecific peaks that also have late retention times. Therefore, GABA
separation was considered an end-point for the optimization of amino acid
detection in dialysis samples and was achieved by changing the gradient
proportionality. To better resolve GABA from other co-eluting peaks, the
percentage of methanol used in the gradient was increased from 40%,
which is optimal for glutamate detection, to 50% methanol. The optimum
flow rate for glutamate and GABA detection with this method was found to
be 2 mL/min and all the runs was performed at ambient temperature with
a monolithic column. Representative HPLC chromatograms (Figure 3-3)
show the separation of glutamate and GABA from standards (100 nM; Fig.
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3-3A) and from dialysis samples (Fig. 3-3B) using these optimized
conditions.
Samples were injected every 15 min following completed NDA
derivatization. The basal levels of GABA and glutamate in the CPu of
C57Bl/6 mice using these optimized conditions were 63 ± 11 nM and 440
± 64 nM, respectively. These values are comparable with previously
reported values where GABA and glutamate concentration in CPu were
approximately 34 and 400 µM, respectively.26
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Figure 3-3. Representative chromatograms illustrating the separation of
glutamate and GABA from (A) standards and from (B) microdialysis
samples from the dorsal striatum (CPu) of mice.
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CHAPTER FOUR
MICRODIALYSIS EXPERIMENTS
Four different microdialysis experiments were conducted to evaluate
the effects of low endogenous levels of BDNF, ethanol, age, and Mn on
extracellular GABA and glutamate in CPu of mouse brain. To analyze the
microdialysis

samples

for

GABA

and

glutamate

optimized

HPLC

parameters described in chapter three were used.
Experiment 1: To evaluate the effects of high K+ on the release of glutamate
GABA in BDNF WT and BDNF+/- mice.
Although the concentration of glutamate and GABA are higher than
that of monoamine neurotransmitters in the microdialysis samples it does
not necessarily indicate that they have neuronal origin. To demonstrate
that

the

extracellular

glutamate

and

GABA

levels

measured

by

microdialysis are neuronally-derived, neurons were depolarized using high
K+ (120 mM KCl) aCSF. High K+ perfusion stimulates neuronal firing by
depolarizing the nerve terminals in the vicinity of microdialysis probe.
To evaluate the effect of BDNF on K+-stimulated neuronal firing in
the CPu, a similar high K+ aCSF perfusion experiment was performed in
BDNF heterozygous (BDNF+/-) mice. BDNF+/- mice lack one copy of the
BDNF gene and hence have an approximate 50% reduction in BDNF
levels.23 BDNF belongs to the neurotrophin family of growth factors, which
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also includes nerve growth factor, neurotrophin 3, and neurotrophin 4.
BDNF, a 27 kDa homodimeric protein, is the most abundant neurotrophic
factor in the brain.1 In general, neurotrophins are synthesized and
released by neurons to support neuronal growth, differentiation, function,
.survival and plasticity.1,30 Several lines of evidence also suggest there is
an important interaction between BDNF and amino acid neurotransmitter
systems. For instance, glutamatergic and GABAergic neurotransmission
increased BDNF mRNA expression in the hippocampus.30 In turn, BDNF
modulates

transmitter

release

in

both

glutamate

and

GABAergic

synapses.30
The elevation in the extracellular levels of GABA and glutamate following
20 min high K+ stimulation in both wildtype and BDNF+/- are shown in the
representative chromatogram in Figure 4-1. Stimulation with high K+
aCSF resulted in a 25- fold and 4-fold increase in GABA (Figure 4-2A) and
glutamate (Figure 4-2B) levels, respectively in CPu in both types of mice.
Two way analysis of variance (ANOVA) revealed that there was a
significant effect of time for both GABA (F14,195=7.29) and glutamate
(F14,210=10.6) indicating high K+ stimulated enhanced release. The amount
increased in GABA and glutamate by K+ stimulation compare to their
basal levels are consistent with previously reported data.11,27
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Figure 4-1. Representative chromatograms from pre- and post-potassium
stimulation. Effect of high K+ stimulation on the extracellular levels of
amino acid neurotransmitters measured by microdialysis in the dorsal
striatum (CPu) of mice. The pink line on the chromatogram shows a
baseline sample before K+ stimulation and black line shows the third
dialysate sample collected 40 min following K+ perfusion.
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Experimental variability in stimulated levels of neurotransmitters is
often attributed to the amount of K+ that diffuses from the perfusate to the
brain tissue, which depends on the membrane tortuosity and perfusion
flow rate.28 The maximum effect of K+ stimulation on extracellular GABA
and glutamate was observed about 40 min after high K+ aCSF perfusion.
K+-stimulated release of glutamate was smaller than the effect of K+ on
GABA. This difference may be due to the rapid activation of glutamate
transporters

and

subsequent

re-uptake

of

glutamate

back

into

presynaptic terminals in surrounding tissue by high concentrations of
K+.28,29
No difference was observed in the basal levels of either GABA or
glutamate in the CPu between wildtype and BDNF+/- mice (Figure 4-3A). In
BDNF+/- mice, the basal levels of GABA and glutamate were found to be 59
± 27 nM and 290 ± 62 nM, respectively. K+-stimulated GABA release was
also unaltered in the CPu of BDNF+/- mice compared to wildtype mice
(Figure 4-3B). Alternatively, a two-tailed t-test revealed a significant
difference in K+-stimulated release of glutamate between wildtype and
BDNF+/- mice (t=3.415, p<0.01) (Figure 4-3B). These data are consistent
with previous studies, which reported that BDNF enhanced glutamate
release but either reduced or had no effect on GABA transmission.32,

33

BDNF may enhance the release of glutamate through activation of the
TrkB receptor, which in turn activates phospholipase C (PLC) and
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produces inositol triphosphate (IP(3)). PLC and IP(3) can initiate the
release of Ca2+ from intracellular stores and thereby enhance the release
of neurotransmitters from presynaptic vesicles.34
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Figure 4-2. Extracellular basal and stimulation-induced GABA and
glutamate levels determined by in vivo microdialysis in BDNF WT and
BDNF+/- mice. The response of elevated K+ (120 mM) on extracellular (A)
GABA and (B) glutamate levels in the dorsal striatum (CPu) of wildtype
(n=8) and BDNF+/- (n=7)mice.
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Figure 4-3. Summary of extracellular basal and stimulation-induced
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined
by in vivo microdialysis in BDNF-deficient mice. (A) Mean baseline levels of
GABA and glutamate not corrected for probe recovery in wildtype (n=8)
and BDNF+/- (n=8) mice. (B) Area under the curve analysis of high K+ (120
mM) stimulation of GABA and glutamate in the CPu in wildtype (n=8) and
BDNF+/- (n=8) mice. Data are mean ±SEM. * p < 0.05 compared to wildtype
mice (two-tailed t-test).
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Experiment 2: To evaluate the effects of ethanol on striatal extracellular
concentrations of GABA and glutamate in BDNF WT and BDNF+/- mice.
Alcoholism is a major health problem among people worldwide. In
the United States, it is estimated that over 14 million Americans suffer
from chronic neuropsychiatric disorders related to alcoholism.35 Many
neurotransmitter systems, including amino acid neurotransmitters, are
affected by ethanol. Ethanol is a small molecule that interacts with
various ligand-gated ion channels, GABA receptor complexes, and
glutamate receptors. For instance, ethanol has been shown to enhance the
function of GABAA receptors as well as reduce the function of NMDA
receptors.36,37 In the case of GABA, it has been suggested that activation
of GABA autoreceptors after ethanol administration would reduce the
output of GABA.38 While some studies have shown that an acute ethanol
injection (2g/kg) reduces extracellular levels of GABA and glutamate,
others have reported this treatment has no effect on either GABA or
glutamate transmission.38,39,40 Since most of these studies were conducted
in the rat nucleus accumbens, the purpose of the current study was to
further evaluate the effect of ethanol on dorsal striatal extracellular GABA
and glutamate levels in mice.
In this study, both wildtype and BDNF+/- mice were treated with a
systemic injection of 2 g/kg ethanol (i.p.), which was shown to elicit
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behavioral changes acutely in animals.41 As described in Experiment 2,
BDNF+/- mice have low endogenous levels of BDNF and were used in this
experiment to evaluate the effect of reduced BDNF levels on ethanolevoked changes in GABA and glutamate transmission. After the collection
of three baseline samples (30 min), mice received a saline injection prior to
ethanol administration to observe if animal handling during the injection
would have a stress-induced effect on the extracellular levels of glutamate
and GABA. Four dialysis samples were collected following the saline
injection. Overall, there was no difference in the levels of either
extracellular GABA or glutamate after a saline injection (Figure 4-4 A and
B).

Analysis

of

the

dialysis

samples

collected

following

ethanol

administration revealed that the ethanol-induced glutamate levels were
unaltered in both wildtype and BDNF+/- mice (Figure 4-4B). Alternatively,
ethanol promoted the release of GABA in both wildtype and BDNF+/- mice
30 min after injection (Figure 4-4A). Ethanol enhanced the extracellular
level of GABA by approximately 4-fold, which returned to baseline levels
70 min after the ethanol injection. Although ethanol stimulated GABA
release in both wildtype and BDNF+/- mice, the peak GABA release is
slightly reduced in BDNF+/- mice. Following area under the curve analysis,
the effect of ethanol to increase extracellular GABA was not statistically
different (t=2.065, p > 0.05) between wildtype and BDNF+/- mice (Figure 45) when evaluated using a t-test.
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Together, these results indicate systemic ethanol administration has
no effect on the levels of extracellular glutamate but stimulates an
increase in the levels of extracellular GABA. While the lack of effect of
ethanol on glutamate transmission agrees with previous reports40,42 the
changes in GABA are contradictory to previously reported findings with
ethanol in the nucleus accumbens (i.e. reductions in GABA output).12,41
Since the current data were collected in the dorsal striatum, this may
indicate the effect of ethanol to increase GABA output is regionally
specific. For instance, it has been suggested that activation of GABAB
autoreceptors

in

some

brain

regions

enhancement of GABA transmission.43

might

mask

ethanol-evoked
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Figure 4-4. Saline and ethanol (EtOH)-stimulated extracellular GABA and
glutamate levels in the dorsal CPu of BDNF deficient mice. (A)
Extracellular GABA concentration was increased in both WT and BDNF+/mice after an acute injection of ethanol. (B) No difference in extracellular
glutamate levels between the genotypes (WT n=4; BDNF+/- n =3).
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Figure 4-5. Area under curve analysis for the GABA peak for wildtype
(WT; n=4) and BDNF+/- (n=3) after ethanol administration. For area under
the curve analysis time points from 80 – 150 min were analyzed. Data are
the means ± S.E.M.
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Experiment 4: To evaluate the effect of manganese exposure on the
extracellular concentration of GABA in the CPu.
Manganese (Mn) is an essential trace element in the body. It has
many important biological roles, such as a co-factor for key enzymes that
regulate metabolism, reproduction, digestion, blood clotting.50 Unlike
other trace elements, such as zinc and iron, Mn can accumulate to toxic
levels in the brain, particularly in individuals with routine occupational
exposure (i.e. welders, miners, and steel workers).49 Iron (Fe) deficiency is
another factor that appears to facilitate Mn accumulation.50 Since Mn
competes with Fe for transport through divalent metal transporters, less
Fe in the body enhances the absorption of Mn in the tissue. Most studies
have linked Mn neurotoxicity, which manifest in a syndrome known as
manganism,

with

alterations

in

dopamine

neurotransmission.50,51

However, recent studies have indicated that other neurotransmitters,
particularly GABA, are affected by Mn accumulation.50,52
Based upon these previous studies, the effect of Mn accumulation
on extracellular basal levels and K+ release of GABA was measured in the
striatum of mice. Administration of 120 mM K+ for 20 min enhance the
release of GABA in both control and Mn-treated mice at each time point
after cessation of Mn-treatment (Figure 4-8A,B and C) The extracellular
concentration of GABA was increased on day 2 following repeated
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systemic

injections

of

Mn

(50 mg/kg)

(Figure

4-9A). GABA

was

significantly increased by ~ 22% in Mn treated mice compared to control
mice on day 2 (t=2.453, p < 0.05). However, extracellular GABA levels were
similar in Mn treated mice relative to control mice on day 8 and 22 after
treatment. This finding correlates with the previous observations that Mn
levels are typically elevated in the brain immediately following Mn
treatment but return to normal levels by day 14.53,
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Conversely, area

under the curve analysis indicates K+-stimulated (120 mM) GABA release
was unaltered by Mn treatment on any treatment day compared to control
conditions (Figure 4-9B).
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Figure

4-8.

Extracellular basal and stimulation-induced GABA levels
determined by in vivo microdialysis in Mn-treated mice The effect of elevated K+

(120 mM) on extracellular GABA in mice treated with Mn (n=4) showed no
difference compared to control (saline treated mice. Stimulated GABA
levels were measured (A) 2, (B) 8, and (C) 22 days after Mn treated and
control mice (n=4).
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Figure 4-9. Summary of extracellular basal and stimulation-induced
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined
by in vivo microdialysis in Mn treated mice. (A) Baseline levels of GABA in
Mn treated (n=4) and control mice (n=4) at 3 discrete time points after Mntreatment. (B) Area under curve for the K+ stimulated release of GABA in
Mn treated and control mice.

62

In summary, these data suggest elevated levels of Mn in the brain
enhance the extracellular levels of GABA in the striatum, without altering
stimulated release. The elevated extracellular GABA levels in the dorsal
striatum agrees with a previous finding where an increase in extracellular
GABA levels in striatum was seen in rats exposed to a high Mn diet.50
Previous studies have suggest that Mn upregulates GABAA ionotropic
receptors and also dose dependently bind to GABAB autoreceptors and
inhibit it’s function.55,56 Therefore, increased levels of extracellular GABA
maybe due to regulation of GABAB autoreceptor function and upregulation
of GABAA receptor function by Mn.

Although it has been shown that Mn

exposure reduces GABA tissue levels in the striatum in rats54, according
this result there is no significant difference in high K+ stimulated release
in GABA in Mn treated mice compare to controls.

63

Experiment 4: To evaluate the effect of age and low endogenous BDNF
levels on the extracellular concentrations of glutamate and GABA in the
CPu.
Despite the brain’s intrinsic compensatory processes, it has been
shown functional and morphological changes in the brain with age. These
age-related changes include loss of neurons and structural proteins as
well as a reduction in the levels of neurotransmitters, their precursor
molecules, and receptor binding sites, and reduction of the activity of
enzymes involve in the synthesis of neurotransmitters.44,45 Often, these
changes are directly linked to age-associated abnormalities, such as loss
of motor function and deficits in learning and memory.46 Sometimes these
changes

are

brain-region

specific.

In

the

case

of

amino

acid

neurotransmitters, rodent aged-studies have shown a decrease in
glutamate and GABA receptors in the hippocampus, a reduction of the
GAD enzyme primarily in cortex and thalamus, and a decrease in the
number of presynaptic terminals.47 Overall, these changes would indicate
amino

acid

transmission

is

reduced

in

the

aged

brain.

Indeed,

Huntington’s disease has been associated with the loss of GABA signaling
in the striatum.48
In light of the studies demonstrating age-related changes in
glutamate and GABA, the current study compared the basal and
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stimulated levels of both amino acid neurotransmitters in the striatum of
young (approximately 3-6 months old) and aged (18 months old) mice. In
aged mice, there was a significant increase (t=5.547, p <0.001) in the
basal levels of extracellular GABA (340 ± 50 nM) compared to adult mice
(63 ± 11 nM) (Figure 4-7A). Alternatively, no significant difference was
observed in the baseline levels of extracellular glutamate between adult
and aged mice (Figure 4-7A). Alteration of extracellular GABA and
glutamate levels in the CPu of young and aged mice were measured
following high K+ stimulation. The release of both GABA and glutamate in
aged mice after K+ stimulation was considerably less compare to that of
young mice (Figure 4-6A and B). Two way ANOVA revealed that there was
a significant effect of age for K+ stimulated release of both GABA
(F1,96=10.32) and glutamate (F1,98=7.45). To compare the potassiumstimulated release between young and aged mice, area under curve for the
potassium stimulated release was determined for each mouse (Figure 47B). According to the t-test potassium-stimulated release of both GABA
(t=2.363, p=0.05) and glutamate (t=3.551, p=0.01) were significantly
decreased in aged mice compared to young mice with about 60% decrease
in

GABA

and

46%

decrease

in

glutamate.

Together,

this

study

demonstrates basal extracellular GABA levels increase in the CPu with
age, while stimulated release of both GABA and glutamate were
attenuated in aged mice compared to young mice. Particularly, this study
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shows significant age-related changes in both basal and high K+ release
levels of GABA. Increase level of basal GABA might be due to reduced
function of GABA transporters and GABA autoreceptors with age.
Altogether,

these

data

demonstrate

altered

GABA

and

glutamate

neurotransmitter function in CPu in aged mice which may make them
more susceptible to various age-related neurological diseases.
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Figure 4-6. Extracellular basal and stimulation-induced GABA and
glutamate levels determined by in vivo microdialysis in young and aged
wildtype mice. High K+ (120 mM) aCSF was perfused directly through the
dialysis probe and extracellular GABA (A) and glutamate (B) in the CPu of
wildtype young (n=8) and aged mice (n=4) were evaluaed. Data are the
means ± S.E.M.
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Figure 4-7. Summary of extracellular basal and stimulation-induced
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined
by in vivo microdialysis in young and aged mice. (A) Extracellular basal
levels of GABA and glutamate in wildtype young (n =8) and aged (n=4)
mice. ***P <0.001, compare to the adult mice (student’s t-test). (B) Area
under the curve for the potassium stimulation release of GABA and
glutamate in wildtype adult and aged mice. Data are the means ± S.E.M.
**p < 0.001 (two-tailed t-test)

68

CHAPTER FIVE
ANALYSIS OF TISSUE CONTENT
Table 1 summarizes the results obtained for GABA and glutamate
levels on the frontal cortex, hippocampus, and striatum of male C57BL/6
mice. Among these three brain regions, frontal cortex shows the highest
concentration of both glutamate and GABA. Analysis of GABA and
glutamate tissue content was also performed by the optimized HPLC
method coupled to pre-column derivatization by NDA (see Chapter 3 ).
Detector sensitivity was set at low since the intensities for the amino acids
are high. As previous methods mentioned, one of the amino acid that
interfere with glutamate detection in tissue samples is N-acetyl-aspartate
(NAA).11,12 NAA is known to co-elute with glutamate peak because the
concentration of NAA is much higher in tissues and its retention is similar
to glutamate. However, our derivatization method uses NDA, which reacts
with only primary amino acids and since NAA is a secondary amino acid,
it was not derivatized by NDA in this method.
For NDA-amino acids reaction, pH greater than 9.5 is required. In
biological samples the amino group of amino acids (-NH2) present as
protonated (-NH3+). NDA reacts with only nonprotonated NH2 group.12
Therefore, the NDA reaction requires a buffer having a pH greater than
9.5, which is the approximate pKa of the amino groups. The problem
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associated with tissue analysis by NDA was the homogenizing buffer
contained HClO4, thus the pH of the homogenizing buffer is less than 2
and adding the derivatizing reagents (NDA, and KCN, and borate buffer at
pH 9.5) to the homogenate did not derivatize the amino acids in the
sample. With this homogenizing buffer, which was not sufficiently basic to
derivatize the amino acids, thus, an additional step was preformed. Borate
buffer (pH 9.5) was added to the samples after the homogenization to
make the pH of the sample neutral (~pH 7.0-7.4). Since all the punches
are approximately same weight (~3 mg), a constant volume (provide
volume) of homogenizing buffer was added to all the samples
Analysis of GABA and glutamate tissue content was done in frontal
cortex, hippocampus, and striatum. Among these three brain region
frontal cortex shows the highest concentration of both GABA and
glutamate. These values are consistent with previous reported values.25,28
Future work with this preliminary study will compare the tissue content of
GABA and glutamate tissue levels as measured by HPLC-fluorescent
detection to values obtained by magnetic resonance spectroscopy.
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Brain region

GABA (µM/g)

Glutamate (µM/g)

Frontal Cortex

33.0 ± 2.0 (n=5)

139.0 ± 8.0 (n=5)

Hippocampus

1.8 ± 0.04 (n=5)

11.0 ±0.019 (n=5)

Striatum

2.2 ±0.03 (n=5)

3.4 ± 0.2 (n=5)

Table 5-1. GABA and glutamate levels from tissue punches obtained from
the frontal cortex, hippocampus, and striatum of C57Bl/6J mice. Results
are expressed as mean ± S.E.M.
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CHAPTER SIX
Conclusions
GABA and glutamate are important amino acid neurotransmitters in
the central nervous system (CNS), since they have essential roles as the
major inhibitory and excitatory transmitter systems, respectively. As a
result, altered levels of GABA and glutamate underlie several neurological
diseases.6 The ability to measure the dynamics of GABA and glutamate
transmission, by detecting changes in extracellular and tissue levels in
different brain regions, will thus lead to a better understanding of the
etiology of these dysfunctions and effective pharmacotherapies. In
neurochemistry laboratories, HPLC is a prevalent method used to detect
neurotransmitters, since it is commercially available and easy to setup.
One of the challenges in the detection of amino acid transmitters is that
they are not electroactive or fluoresce. To overcome these chemical
limitations, pre-column derivatization can be done. This thesis describes
the optimization of pre-column derivatization of GABA and glutamate by
NDA/CN- for analysis by HPLC employing a monolithic column. In a direct
comparison to OPA derivatization, NDA fluorescent products of GABA and
glutamate were very stable and could be separated in less than 5 min with
a total sample run time of 10 min.
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This optimized method was then used to monitor changes in
extracellular levels of GABA and glutamate in vivo using off-line coupled
microdialysis. In this thesis, microdialysis was used to study the effects of
1) high K+ stimulation, 2) low endogenous levels of BDNF, 3) acute
administration of ethanol, 4) age, and 5) Mn accumulation on GABA and
glutamate transmission in the CPu of freely-moving mice.
1. How BDNF influences baseline and stimulated GABA and
glutamate in the CPu.
Mice that have approximately a 50% decrease in BDNF showed that
no differences in extracellular GABA and glutamate levels in the dorsal
CPu. However, upon a 20 min high K+ stimulation demonstrated that the
release mechanism is significantly reduced for glutamate only in BDNF+/mice. The BDNF data implicate a role for BDNF to regulate striatal
glutamate neurotransmission, which are consistent with previously
published reports. However, when a locomotor-stimulating dose of ethanol
(2 kg/g) was administered no differences were observed between the
wildtype and BDNF+/- mice. Although no precise mechanism has been
identified for how ethanol regulates striatal amino acids level, an acute
injection of ethanol elevated extracellular GABA in the CPu, while
glutamate levels were insensitive to ethanol treatment. Further studies are
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required to better understand how extracellular GABA and glutamate
levels respond to alcohol in both the dorsal and ventral striatum.
2. How age influences baseline and stimulated GABA and glutamate
in the CPu.
In vivo microdialysis was used to determine whether the effect of age
selectively alters extracellular GABA and glutamate levels in the dorsal
CPu. Extraneuronal GABA levels without correction for probe recovery
averaged over 3 baseline samples per mouse showed a significant increase
in aged mice. However, there was no difference in extraneuronal glutamate
levels between the young and aged mice. To investigate whether
alterations in stimulated GABA and glutamate release might be associated
with age, high K+ was perfused via reverse dialysis into the striatum
during the period 30 – 50 minute after baseline sample collection was
initiated. GABA was maximally elevated ~21-fold above baseline in young
mice, while a ~6-fold above baseline was observed in aged mice.
Glutamate was maximally elevated ~3- and 4-fold above baseline in aged
and young mice, respectively. The age-related declines in potassiumstimulated extracellular levels of GABA and glutamate suggest these
neurotransmitters are sensitive to modification in the aging brain.
However, the finding that basal extracellular levels of GABA but not
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glutamate are altered in aged mice illustrate that neurotransmitters are
not always equally sensitive to aging effects.
3. How manganese exposure effects extracellular concentrations of GABA in
the CPu.
Recent studies highlight that excessive exposure of Mn can
influence a variety of striatal neurotransmitter systems such as dopamine,
norepinephrine, and GABA.54,55 In vivo microdialysis was used to
determine whether a sub-acute Mn treatment selectively alters striatal
extracellular GABA levels. Extraneuronal GABA levels without correction
for probe recovery showed no difference 8 or 22 days after Mn-treatment.
However, a significant increase was observed 2 days after a sub-acute Mntreatment. These results suggest that a sub-acute Mn treatment have an
imminent effect on extracellular GABA levels, but that this effect
dissipates within 6 days. Although an increase in extracellular levels was
observed in Mn-treated mice, no difference was observed between control
and treated mice with respect to alterations in stimulated GABA release by
high

K+

aCSF.

Taken

together,

these

results

suggest

that

Mn

accumulation can induce a transient increase in extracellular GABA levels
that are not affected by robust stimulation on day 2. Further studies are
required to determine if these significant but transient increases in
extracellular GABA levels following Mn accumulation are involved in the
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locomotor

deficits

associated

with

Mn

neurotoxicity,

including

hyperkinesias, ataxia, and dystonia.50
Collectively, this thesis describes the development of a reproducible
and accurate HPLC-based method, which can reliably be coupled with
microdialysis to measure biologically relevant changes in extracellular
GABA and glutamate levels. Interesting the most robust alterations in the
extracellular striatal GABA and glutamate levels were uncovered in aged
mice, while a significant decrease in extracellular glutamate levels was
observed in BDNF+/- mice only after high potassium stimulation, and
finally a modest increase was observed in extracellular GABA only in Mntreated mice. The results within this thesis highlight the importance of
monitoring amino acid neurotransmitters such as GABA and glutamate
under various conditions such as low endogenous BDNF levels, age, or
excess accumulation of Mn by in vivo microdialysis to better understand
the dynamics of these neurotransmitters.
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GABA and glutamate are the predominant inhibitory and excitatory
amino acid neurotransmitters in the central nervous system (CNS),
respectively. However, their altered levels cause several neurological
diseases including Parkinson’s and Huntington’s disease, schizophrenia,
and epilepsy. It is important to measure their levels in the extra- and
intracellular environments to better understand and develop improved
therapeutics that will treat these neurological disorders. The principle aim
of this study is to study the impacts of different endogenous and
exogenous factors on the striatal extracellular GABA and glutamate levels.
The first objective was to develop a method to analyze GABA and
glutamate using HPLC coupled to fluorescence detection. The second
objective was to evaluate the effects of BDNF, age, ethanol, and Mn
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exposure on the striatal GABA and glutamate levels. Using a monolithic
column, GABA and glutamate were separated in dialysis samples at 2 and
4.5 minutes, respectively. Low levels of endogenous BDNF, acute
administration of ethanol (2 g/kg), and age differently affect the GABA and
glutamate levels. In BDNF+/- mice potassium stimulated release of
glutamate was significantly reduced while release of GABA was not
different between wildtype and BDNF+/- mice. Administration of ethanol
increased extracellular levels of GABA in both wildtype and BDNF+/- mice.
The impact of age on striatal extracellular GABA and glutamate levels was
evaluated in mice 3 and 18 months old. Aged mice showed a significant
reduction in both high K+-stimulated GABA and glutamate release.
The final study evaluated the effect of a sub-acute Mn treatment on
striatal extracellular GABA levels, where a modest but significant increase
in extracellular GABA was observed 2 days after Mn treatment.

Taken

together, these findings reveal that extracellular GABA and glutamate are
differentially affected by BDNF, ethanol, age, and Mn.
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